<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02456480</url>
  </required_header>
  <id_info>
    <org_study_id>CLS001-CO-PR-008</org_study_id>
    <secondary_id>2014-003689-26</secondary_id>
    <nct_id>NCT02456480</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics of Omiganan (CLS001) in Patients With Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-blind, Placebo Controlled Study to Assess the Pharmacodynamics, Safety/Tolerability and Efficacy of Omiganan in Patients With Mild to Moderate Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutanea Life Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutanea Life Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the pharmacodynamics, safety/tolerability, and efficacy of omiganan in patients
      with mild to moderate atopic dermatitis (AD).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamic (Local punch biopsy of a target lesion pre-dose and post treatment for the change in biomarkers including IL, filaggrin, TLR, IgE, IFN, and microbiome of the skin lesion)</measure>
    <time_frame>42 Days</time_frame>
    <description>Local punch biopsy of a target lesion pre-dose and post treatment for the change in biomarkers including IL, filaggrin, TLR, IgE, IFN, and microbiome of the skin lesion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical assessment (Change in patient symptoms over time using pruritis VAS)</measure>
    <time_frame>42 Days</time_frame>
    <description>Change in patient symptoms over time using pruritis VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Assessment (Change in lesion size over time)</measure>
    <time_frame>42 Days</time_frame>
    <description>Change in lesion size over time</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical assessment (Change in patient SCORAD scale score over time)</measure>
    <time_frame>42 Days</time_frame>
    <description>Change in patient SCORAD scale score over time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Assessment (Adverse events)</measure>
    <time_frame>42 days</time_frame>
    <description>Adverse events will be collected throughout the study</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">37</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>CLS001 topical gel, 2.5%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CLS001 topical gel 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CLS001</intervention_name>
    <description>topical gel</description>
    <arm_group_label>CLS001 topical gel, 2.5%</arm_group_label>
    <arm_group_label>CLS001 topical gel 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>topical gel</description>
    <arm_group_label>Vehicle gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects with mild to moderate AD 18 to 65 years of age, inclusive.

          2. AD diagnosed by physician / medical specialist and that has been (intermittently)
             present for at least 1 year

          3. Able to participate and willing to give written informed consent and to comply with
             the study restrictions.

        Exclusion Criteria:

          1. Have any current and / or recurrent clinically significant skin condition in the
             treatment area other than AD.

          2. Any confirmed, active significant allergic reactions (urticaria or anaphylaxis)
             including allergic reactions against any drug, multiple drug allergies or (ingredients
             of) emollients.

          3. Participation in an investigational drug or device study within 3 months prior to
             screening or more than 4 times a year.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>J. (Koos) Burggraaf, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Human Drug Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Human Drug Research</name>
      <address>
        <city>Zernikedreef 8</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <disposition_first_submitted>July 25, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>July 25, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">July 28, 2016</disposition_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

